Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14024989 | 0.89 | HRH3 (0.49) | ALDH1A1HRH3CYP2D6PARP1MAPT | |
| SCHEMBL12026487 | 0.82 | ALDH1A1 (0.54) | ALDH1A1HRH3CYP2D6PARP1MAPT | |
| SCHEMBL2948497 | 0.82 | ALDH1A1 (0.58) | ALDH1A1HRH3CYP2D6PARP1MAPT | |
| SCHEMBL25564115 | 0.81 | ALDH1A1 (0.50) | ALDH1A1HRH3CYP2D6PARP1MAPT | |
| SCHEMBL13300924 | 0.81 | ALDH1A1 (0.50) | ALDH1A1HRH3CYP2D6PARP1MAPT | |
| SCHEMBL2609287 | 0.81 | ALDH1A1 (0.53) | ALDH1A1HRH3CYP2D6MAPTACKR3 | |
| SCHEMBL16158913 | 0.81 | ALDH1A1 (0.45) | ALDH1A1HRH3CYP2D6PARP1MAPT | |
| SCHEMBL27097201 | 0.81 | ALDH1A1 (0.45) | ALDH1A1HRH3CYP2D6PARP1MAPT | |
| SCHEMBL13300923 | 0.80 | ALDH1A1 (0.49) | ALDH1A1HRH3CYP2D6PARP1MAPT | |
| SCHEMBL13663382 | 0.79 | ALDH1A1 (0.51) | ALDH1A1HRH3CYP2D6PARP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. | 2020-06-04 | — | — | US | disclosed |
| US-8163740-B2 | 6-substituted benzoxazines | HOFFMANN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110160196-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100063037-A1 | 6-SUBSTITUTED BENZOXAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | US | disclosed |
| CN-100457753-C | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases | BRISTOL MYERS SQUIBB CO (US) | 2009-02-04 | — | — | CN | disclosed |
| US-20080293704-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293704-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| CN-1444584-A | N- [ 5- [ [ [ 5-alkyl-2-oxazolyl ] methyl ] thio ] -2-thiazolyl ] carboxamide inhibitors of cyclin dependent kinases | BRISTOL MYERS SQUIBB CO (US) | 2003-09-24 | — | — | CN | disclosed |
| CN-1433416-A | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamideinhibitors of cyclin dependent kinases | BRISTOL MYERS SQUIBB CO (US) | 2003-07-30 | — | — | CN | disclosed |
| CN-1370144-A | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | SEARLE & CO (US) | 2002-09-18 | — | — | CN | disclosed |
| CN-1279669-A | Aromatic sulfone hydroxamic acid metalloprotease inhibitors | SEARLE & CO (US) | 2001-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | PIM1, PIM3, PIM2 | ALDH1A1 405/4885HRH3 1924/4885CYP2D6 574/4885 |
| US-20080293704-A1 | FACTOR Xa INHIBITORS | TFPI, F12, F11 | ALDH1A1 1468/4885HRH3 1555/4885CYP2D6 440/4885 |
| US-20110160196-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | ALDH1A1 1468/4885HRH3 1555/4885CYP2D6 440/4885 |
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | PTPRJ, PTPN2, PTPN5 | ALDH1A1 2732/4885HRH3 4514/4885CYP2D6 3453/4885 |
| US-20100063037-A1 | 6-SUBSTITUTED BENZOXAZINES | HTR5A, NPY5R, GABRA5 | ALDH1A1 1883/4885HRH3 160/4885CYP2D6 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.